Core Insights - Insight Molecular Diagnostics Inc. (iMDx) is actively participating in two significant industry conferences to showcase its GraftAssure™ technology and its clinical kitted test under development [1][4] - The company aims to highlight the clinical applications of transplant rejection testing, particularly in longitudinal surveillance and therapeutic response monitoring [2][3] Conference Participation - iMDx is hosting a symposium at the IATDMCT annual meeting in Singapore from September 21 to 24, 2025, focusing on the benefits of in-house testing for transplant rejection [2][6] - The company will also present at the ASHI annual meeting in Orlando, Florida, from October 6 to 10, 2025, discussing GraftAssureIQ, a research-use-only test kit [4][8] Technology and Product Development - GraftAssure technology is designed to detect transplant rejection and monitor treatment response, significantly reducing time-to-rejection diagnosis in high-risk kidney transplant patients [3][5] - The GraftAssureDx, currently in development, is expected to be submitted for FDA review by the end of 2025, targeting an estimated $1 billion addressable market for kitted transplant rejection testing [5][15] Strategic Partnerships - iMDx is collaborating with Bio-Rad Laboratories to present on GraftAssureIQ, emphasizing the potential of in-house testing for convenience and efficiency in transplant care [4][5] Market Position - The company is focused on democratizing access to molecular diagnostic testing, particularly for kidney transplant patients, utilizing donor-derived cell-free DNA (dd-cfDNA) as a biomarker for transplant rejection [16][13]

FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized as a Greater Pittsburgh Top Workplace by The Pittsburgh Post-Gazette. The designation is based exclusively on anonymous employee feedback gathered through a third-party survey. The confidential survey measures several aspects of workplace culture designed to be indicative of employee satisfacti ...

MISSISSAUGA, Ontario and MANCHESTER, United Kingdom, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the go-live of a program to support rapid and accurate identification of patients who carry gene-variants associated with faster and slower than normal metabolism of the wide ...

Core Insights - Hologic and Thermo Fisher Scientific are key players in the diagnostics market, each with distinct strengths and market focuses [1][2] Hologic Overview - Hologic specializes in molecular diagnostic assays for infectious diseases, particularly in women's health, with a market cap of $14.75 billion [1] - The company has seen strong growth in its Molecular Diagnostics segment, particularly with the BV, CV/TV assay, which has become its second-largest test globally since its launch in 2019 [3] - Hologic's Breast Health business is recovering, with expectations to return to growth by Q4 of fiscal 2025, aided by new leadership and innovations [4] - The company has a strong GYN Surgical portfolio and has expanded its fibroid treatment offerings through the acquisition of Gynesonics [5] - Hologic maintains a solid financial position with $1.88 billion in cash and short-term investments and a net leverage ratio of 0.6 [6] - The company has raised its full-year revenue guidance to $1.03-$1.04 billion and adjusted EPS to $1.09-$1.12, despite facing cost pressures from tariffs [7] Thermo Fisher Overview - Thermo Fisher, valued at $181.10 billion, offers a wide range of diagnostic products and services across various sectors, including healthcare and food safety [2] - The company is experiencing growth in its bioproduction and pharma services, supported by significant innovations and product launches [8] - Thermo Fisher's capital deployment strategy includes strategic acquisitions and shareholder returns, with recent acquisitions aimed at enhancing its bioproduction capabilities [11] - The company has projected revenues between $43.6 and $44.2 billion and adjusted EPS of $22.22-$22.84 for the full year, both raised from prior estimates [13] Performance Comparison - Over the last six months, Hologic's stock has increased by 4.2%, while Thermo Fisher's stock has decreased by 7.7% [9][16] - Hologic's shares are trading at a forward five-year P/E of 14.41X, compared to Thermo Fisher's P/E of 20.12X, indicating a more favorable valuation for Hologic [17] - Analysts project a year-over-year EPS growth of 3.7% for Hologic, while Thermo Fisher's EPS is expected to improve by 3% [19][21] Investment Outlook - Both companies exhibit strong fundamentals and financial stability, with Hologic showing resilience in its growth areas and Thermo Fisher focusing on innovation and market expansion [22]

Core Insights - The collaboration between Lunit and Agilent aims to revolutionize biomarker testing and enhance precision medicine capabilities [1] Company Overview - Lunit is a leading provider of AI for cancer diagnostics and therapeutics [1] - Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets [1] Collaboration Details - The partnership is a nonexclusive collaboration focused on developing AI-based companion diagnostic solutions [1]

MDxHealth SA (NASDAQ:MDXH) is among the best fundamentally strong penny stocks to buy right now. On September 15, 2025, MDxHealth SA (NASDAQ:MDXH) announced the completion of its acquisition of Bio-Techne Corporation’s ExoDx business, including the ExoDx Prostate test. This $15 million transaction is part of the company’s plan to strengthen its precision diagnostics portfolio. Earlier on August 5, 2025, MDxHealth SA (NASDAQ:MDXH) signed a definitive agreement for the takeover with payment structured over ...

Acquisition Details - Labcorp has completed the acquisition of select assets of BioReference Health for up to $225 million, which includes $192.5 million paid at closing and up to $32.5 million in performance-based earnout [5][9] - The acquisition enhances Labcorp's oncology diagnostics portfolio and expands access to high-quality laboratory services and testing capabilities for patients and physicians [6][9] Financial Performance - Labcorp has a market capitalization of $22.78 billion and an earnings yield of 5.9%, which is higher than the industry average of 4% [4] - In the second quarter of 2025, Labcorp invested $25 million in acquisitions and partnerships, indicating a strong pipeline for future growth [3] Market Context - The global cancer diagnostics market is projected to grow at a compound annual growth rate of 6.14% from 2025 to 2030, driven by increasing cancer prevalence and advancements in diagnostic technologies [10] - Labcorp's shares have increased by 20.8% over the past year, outperforming the industry, which has seen a decline of 19.9% [13] Recent Developments - In August, Labcorp expanded its cell and gene therapy laboratory in Madison, WI, enhancing its preclinical testing capabilities [11] - The company also launched a new FDA-cleared blood-based diagnostic test for Alzheimer's disease, further diversifying its service offerings [12]

FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek. The ranking honors 650 U.S. companies demonstrating strong performance across four key pillars: financial strength, workforce dedication, innovation, and commitment to environmental sustainability and corporate ethics. “This recognition from ...

Core Insights - Microbix Biosystems Inc. and Labquality Oy have launched a novel external quality assessment (EQA) program aimed at improving the accuracy of clinical laboratories in identifying HPV-associated head and neck cancers [1][4] - The EQA program is introduced at the 2025 European Society for Clinical Virology meeting and addresses the need for proficiency checks in laboratories performing HPV-related diagnostics [1][4] Group 1: Industry Context - Head and neck cancers (HNCs) are increasingly common, particularly in males, with over 300,000 cases diagnosed annually in North America and Western Europe, representing approximately 4% of all cancers [2] - Accurate identification of HPV-driven HNCs is crucial as these patients have better prognoses, influencing treatment decisions [2] Group 2: EQA Program Details - The EQA program utilizes Microbix's QAPs™ mimetics of HNC patient samples, which include both immunohistochemical (IHC) and PCR targets, to assess laboratory competency [3][5] - A pilot study involving 32 clinical laboratories revealed significant discrepancies in p16 IHC staining protocols, highlighting the need for improved diagnostic accuracy through reflex testing [4] Group 3: Company Profiles - Microbix Biosystems Inc. specializes in creating proprietary biological products for human health, targeting revenues of C$ 2.0 million or more per month, and is involved in the global diagnostics industry [7] - Labquality Oy provides external quality assessment services to over 8,000 customers in more than 60 countries, focusing on enhancing laboratory proficiency and patient care [9]

PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced an expansion of its blood-based testing capabilities in partnership with EmeritusDX, a rapidly growing cancer diagnostics and information company. The two companies are building out their best-in-class product portfolios and respective infrastructures to meet growing clinical demand fo ...